Differenze
Queste sono le differenze tra la revisione selezionata e la versione attuale della pagina.
| Entrambe le parti precedenti la revisioneRevisione precedenteProssima revisione | Revisione precedente | ||
| dashboard:report_kpm_von_2013-2024 [2025/07/02 21:19] β [π Chronic Lung Disease - Recovery Excellence] admin | dashboard:report_kpm_von_2013-2024 [2025/07/04 21:50] (versione attuale) β [π 12-Year Journey Summary] admin | ||
|---|---|---|---|
| Linea 10: | Linea 10: | ||
| | **π΄ CONCERN** | 2/10 | **Significant deviation** | β οΈ **ATTENTION** | | | **π΄ CONCERN** | 2/10 | **Significant deviation** | β οΈ **ATTENTION** | | ||
| - | --- | ||
| - | |||
| - | /* 1. MORTALITY CONTROL CHART (2013-2024)\* | ||
| ===== π Mortality Trend - 12 Year Analysis ===== | ===== π Mortality Trend - 12 Year Analysis ===== | ||
| Linea 87: | Linea 84: | ||
| - **2024:** 2.9% - **Miglior performance bilanciata** della serie storica | - **2024:** 2.9% - **Miglior performance bilanciata** della serie storica | ||
| - **Capability: | - **Capability: | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | ===== π Death or Morbidity - StabilitΓ Controllata ===== | ||
| + | |||
| + | < | ||
| + | { | ||
| + | " | ||
| + | " | ||
| + | " | ||
| + | }, | ||
| + | " | ||
| + | " | ||
| + | }, | ||
| + | " | ||
| + | { | ||
| + | " | ||
| + | " | ||
| + | }, | ||
| + | { | ||
| + | " | ||
| + | " | ||
| + | }, | ||
| + | { | ||
| + | " | ||
| + | " | ||
| + | }, | ||
| + | { | ||
| + | " | ||
| + | " | ||
| + | } | ||
| + | ], | ||
| + | " | ||
| + | " | ||
| + | }, | ||
| + | " | ||
| + | " | ||
| + | " | ||
| + | " | ||
| + | } | ||
| + | } | ||
| + | </ | ||
| + | |||
| + | |||
| + | **Analisi Death or Morbidity: | ||
| + | - **Media storica 12 anni:** 32.1% | ||
| + | - **2024:** 35.3% (sopra media ma sotto UCL) | ||
| + | - **Range:** 19.4% (2018) - 45.8% (2015) | ||
| + | - **Status:** Processo sotto controllo statistico | ||
| + | - **Trend:** VariabilitΓ contenuta entro limiti accettabili | ||
| + | |||
| + | **Key Events:** | ||
| + | - **2015:** Picco massimo 45.8% | ||
| + | - **2018:** Minimo storico 19.4% | ||
| + | - **2024:** Performance controllata, | ||
| --- | --- | ||
| - | /* 2. MAJOR MORBIDITY | + | /*2. ANY LATE INFECTION |
| - | ===== π Death or Morbidity + Late Infection | + | ===== π Any Late Infection |
| < | < | ||
| Linea 98: | Linea 152: | ||
| " | " | ||
| " | " | ||
| - | " | + | " |
| - | " | + | |
| }, | }, | ||
| " | " | ||
| - | " | + | " |
| - | " | + | |
| }, | }, | ||
| " | " | ||
| { | { | ||
| - | " | + | " |
| - | " | + | " |
| - | " | + | |
| }, | }, | ||
| { | { | ||
| - | " | + | " |
| - | " | + | " |
| - | " | + | |
| }, | }, | ||
| { | { | ||
| - | " | + | " |
| - | " | + | " |
| - | " | + | |
| }, | }, | ||
| { | { | ||
| - | " | + | " |
| - | " | + | " |
| - | " | + | |
| }, | }, | ||
| { | { | ||
| - | " | + | " |
| - | " | + | " |
| - | " | + | |
| } | } | ||
| ], | ], | ||
| " | " | ||
| - | " | + | " |
| - | " | + | |
| - | },Β | + | |
| - | " | + | |
| - | " | + | |
| - | " | + | |
| - | " | + | |
| }, | }, | ||
| + | " | ||
| " | " | ||
| - | " | + | " |
| - | " | + | " |
| - | },Β | + | |
| - | " | + | |
| - | " | + | |
| - | " | + | |
| - | {Β | + | |
| - | " | + | |
| - | " | + | |
| - | " | + | |
| - | " | + | |
| - | },Β | + | |
| - | {Β | + | |
| - | " | + | |
| - | " | + | |
| - | " | + | |
| - | " | + | |
| - | }Β | + | |
| - | | + | |
| } | } | ||
| } | } | ||
| Linea 167: | Linea 192: | ||
| **π Key Insights:** | **π Key Insights:** | ||
| - **Late Infection: | - **Late Infection: | ||
| - | - **Death/ | + | |
| --- | --- | ||
| Linea 407: | Linea 432: | ||
| --- | --- | ||
| - | ## 6. NEUROLOGICAL OUTCOMES | + | /* 6. NEUROLOGICAL OUTCOMES\* |
| ===== π Severe IVH & Cystic PVL - Neurological Protection ===== | ===== π Severe IVH & Cystic PVL - Neurological Protection ===== | ||
| Linea 464: | Linea 489: | ||
| --- | --- | ||
| - | ## 7. SEVERE ROP - OPHTHALMOLOGIC EXCELLENCE | + | /* 7. SEVERE ROP - OPHTHALMOLOGIC EXCELLENCE\* |
| ===== π Severe ROP Control Chart - Consistent Excellence ===== | ===== π Severe ROP Control Chart - Consistent Excellence ===== | ||
| Linea 516: | Linea 541: | ||
| --- | --- | ||
| - | ## 8. ANY HUMAN MILK - NUTRITION RECOVERY | + | /*8. ANY HUMAN MILK - NUTRITION RECOVERY\* |
| ===== π Any Human Milk - Complete Recovery Journey ===== | ===== π Any Human Milk - Complete Recovery Journey ===== | ||
| Linea 610: | Linea 635: | ||
| --- | --- | ||
| - | ## 9. COMPREHENSIVE STATISTICAL SUMMARY | + | /*9. COMPREHENSIVE STATISTICAL SUMMARY\* |
| ===== π 12-Year Performance Statistics - All Metrics ===== | ===== π 12-Year Performance Statistics - All Metrics ===== | ||
| Linea 644: | Linea 669: | ||
| --- | --- | ||
| - | ## 10. PROCESS CAPABILITY ANALYSIS | + | /*10. PROCESS CAPABILITY ANALYSIS\* |
| ===== π― 12-Year Capability Assessment ===== | ===== π― 12-Year Capability Assessment ===== | ||
| Linea 678: | Linea 703: | ||
| --- | --- | ||
| - | ## 11. STRATEGIC DASHBOARD & RECOMMENDATIONS | + | /* 11. STRATEGIC DASHBOARD & RECOMMENDATIONS\* |
| ===== π― Strategic Assessment Based on 12-Year Analysis ===== | ===== π― Strategic Assessment Based on 12-Year Analysis ===== | ||
| Linea 765: | Linea 790: | ||
| **Next Chapter:** Focus surgical intervention on 2 remaining challenges (NEC + Pneumothorax) while maintaining the excellence achieved in 8 other key metrics. | **Next Chapter:** Focus surgical intervention on 2 remaining challenges (NEC + Pneumothorax) while maintaining the excellence achieved in 8 other key metrics. | ||
| + | |||
| + | |||
| + | |||
| + | <WRAP left round box 15%> | ||
| + | [[dashboard: | ||
| + | </ | ||
| + | |||